Hologic takes hit in fourth quarter

Article

Hologic has experienced a financially challenging year, due in part to its acquisition of Direct Radiography Corp., and in part to a soft market for bone densitometry. The Bedford, MA, company posted sharply lower fiscal 1999 (end-September) results this

Hologic has experienced a financially challenging year, due in part to its acquisition of Direct Radiography Corp., and in part to a soft market for bone densitometry. The Bedford, MA, company posted sharply lower fiscal 1999 (end-September) results this month, reporting revenues of $84.1 million as compared with $115.6 million in 1998, and a net loss of $3.7 million as compared with net income of $10.4 million the previous year. In its fourth quarter the company saw revenues of $20.1 million, compared with $24.8 million in 1998, and sustained a net loss of $3.2 million, compared with net income of $1.3 million. Without the acquisition of DRC, which was finalized in June (SCAN 6/23/99), Hologic’s net losses would have totaled $315,000 for the fourth quarter and would have been negligible for the fiscal year.

Sales in Hologic’s bone densitometry business were less brisk than the company had hoped, particularly in the U.S. primary care market. Hologic saw decreased demand for its DXA systems, and slower sales of its Sahara ultrasound bone sonometer. In an effort to boost its business, Hologic has bulked up its direct sales team and increased its physician education activities, as well as moving to streamline its U.S. operations, the company said.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
New Mammography Research Examines Impact of High-Resolution DBT
Can Radioligand Therapy Have an Impact for Women with Breast Cancer?
Emerging Concepts in CT-Guided Treatment of Coronary Artery Disease
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.